semaj83/ctmatch_classification huggingface dataset:
Patient description: An 8-year-old male presents in March to the ER with fever up to 39 C, dyspnea and cough for 2 days. He has just returned from a 5 day vacation in Colorado. Parents report that prior to the onset of fever and cough, he had loose stools. He denies upper respiratory tract symptoms. On examination he is in respiratory distress and has bronchial respiratory sounds on the left. A chest x-ray shows bilateral lung infiltrates.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Yellow Fever Able to understand and give informed consent Age 18-45 years or greater than or equal to 55 years If possible, participants agree not to take any vaccines within 30 days before or 30 days after yellow fever vaccination Women of child bearing potential must agree to use effective birth control throughout the duration of the study. A negative urine pregnancy test must be documented prior to vaccination  Travel to or having lived in a country/area which is endemic for yellow fever History of previous yellow fever, West Nile, Dengue, St. Louis encephalitis, Japanese encephalitis vaccination or infection Any history of allergy to eggs, chicken or gelatin or to any previous vaccine A history of a medical condition resulting in impaired immunity (such as HIV infection, cancer, particularly leukemia, lymphoma, use of immunosuppressive or antineoplastic drugs or X-ray treatment). Persons with previous skin cancers or cured non-lymphatic tumors are not excluded from the study History of HIV infection, Hepatitis B or Hepatitis C infection History of any chronic medical conditions that are considered progressive (ex, diabetes, heart disease, lung disease, liver disease, kidney disease, gastrointestinal diseases and uncontrolled hypertension). Use of systemic immunosuppressive medications (ex, prednisone) for 2 weeks or more in the past 3 months History of excessive alcohol consumption, drug abuse, psychiatric conditions, social conditions or occupational conditions that in the opinion of the investigator would preclude compliance with the trial Thymus gland problems (such as myasthenia gravis, DiGeorge syndrome, thymoma) or removal of thymus gland or history of autoimmune disorder Recipient of a blood products or immune globulin product within 42 days of the vaccination visit Pregnant women and nursing mothers or women who are planning to become pregnant for the study duration
Patient description: An 8-year-old male presents in March to the ER with fever up to 39 C, dyspnea and cough for 2 days. He has just returned from a 5 day vacation in Colorado. Parents report that prior to the onset of fever and cough, he had loose stools. He denies upper respiratory tract symptoms. On examination he is in respiratory distress and has bronchial respiratory sounds on the left. A chest x-ray shows bilateral lung infiltrates.

Clinical trial eligibility criteria: eligible ages (years): 1.0-45.0,  Respiratory Sounds Patient and/or parents/guardian signed informed consent Patients with cough or shortness of breath  Chest tubes Skin lesions precluding attachment of sensors Respiratory distress Pregnant women
Patient description: An 8-year-old male presents in March to the ER with fever up to 39 C, dyspnea and cough for 2 days. He has just returned from a 5 day vacation in Colorado. Parents report that prior to the onset of fever and cough, he had loose stools. He denies upper respiratory tract symptoms. On examination he is in respiratory distress and has bronchial respiratory sounds on the left. A chest x-ray shows bilateral lung infiltrates.

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Dengue Virus Dengue Fever Dengue Hemorrhagic Fever Dengue Diseases Healthy as determined by medical history, clinical examination, and biological safety parameters Aged 18 to 45 years on the day of inclusion Informed consent form signed Able to attend all scheduled visits and to comply with all trial procedures For a woman of child-bearing potential, use of an effective method of contraception or abstinence for at least 4 weeks prior to the first vaccination and at least 4 weeks after the last vaccination  History of thymic diseases or thymectomy For a woman of child-bearing potential, known or suspected pregnancy or positive pregnancy test Breast-feeding Current abuse of alcohol or drug addiction that may interfere with the subject's ability to comply with trial procedures Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent Human Immunodeficiency Virus (HIV), Hepatitis B (HBs Ag) or Hepatitis C (HC) seropositivity in blood sample taken at screening Laboratory abnormalities considered clinically significant upon the Investigator's judgment or above the intensity thresholds (defined in the protocol) in blood sample taken at screening Participation in another clinical trial in the 4 weeks preceding the first trial vaccination Planned participation in another clinical trial during the present trial period Previous residence in or travel of more than 2 weeks to areas with high dengue infection endemicity
Patient description: An 8-year-old male presents in March to the ER with fever up to 39 C, dyspnea and cough for 2 days. He has just returned from a 5 day vacation in Colorado. Parents report that prior to the onset of fever and cough, he had loose stools. He denies upper respiratory tract symptoms. On examination he is in respiratory distress and has bronchial respiratory sounds on the left. A chest x-ray shows bilateral lung infiltrates.

Clinical trial eligibility criteria: eligible ages (years): 1.0-11.0,  Encephalitis, Tick-Borne Male and female children will be eligible for participation in this study if they are aged >= 1 years (from the 1st birthday) to 11 years (to the last day before the 12th birthday) at screening their parents / legal guardians provide written informed consent children provide written assent to the study according to age and capacity of understanding their parents/guardians understand the nature of the clinical study and will comply with the requirements of the protocol (e.g., completion of the Subject Diary, return for follow-up visits) they are generally healthy, (i.e. the physician would have no reservations vaccinating with a TBE vaccine outside the scope of a clinical study) provide a negative pregnancy test result at the first medical examination (if the subject is a female and capable of bearing children)  Subjects will be excluded from participation if they have a history of any previous TBE vaccination they have a history of TBE infection they have a history of infection with other flaviviruses they have a history of vaccination against yellow fever and/or Japanese B encephalitis they have a history of severe allergic reactions, in particular a known sensitivity or allergy to any components of the vaccines they are suffering from a disease (e.g. autoimmune disease) or are undergoing a form of treatment (e.g. systemic corticosteroids) that can be expected to influence immunological functions they have received any blood product or immunoglobulins within 90 days prior to study entry they are known to be Human Immunodeficiency Virus (HIV) positive (an HIV test is not required specifically for the purpose of this study) they have a functional or surgical asplenia
Patient description: An 8-year-old male presents in March to the ER with fever up to 39 C, dyspnea and cough for 2 days. He has just returned from a 5 day vacation in Colorado. Parents report that prior to the onset of fever and cough, he had loose stools. He denies upper respiratory tract symptoms. On examination he is in respiratory distress and has bronchial respiratory sounds on the left. A chest x-ray shows bilateral lung infiltrates.

Clinical trial eligibility criteria: eligible ages (years): 0.167-4.917,  Acute Respiratory Infections Pneumonia Children aged 2 to 59 months attending the outpatient's clinics of participating sites WHO defined non-severe pneumonia Accessibility for follow-up Written informed consent by a parent or legal guardian  WHO signs of severe pneumonia recognised by lower chest wall retraction. Children who present with wheezing will be evaluated for lower chest wall indrawing after treatments with nebulised salbutamol. WHO signs of very severe disease/pneumonia defined as any of the following Cyanosis Inability to drink Convulsions Abnormally sleepy or difficult to wake Severe malnutrition recognised by weight for age less than third percentile by the NCHS (National Child Health Statistics) growth chart and/or oedema (see chart) All patients with a previous history of 3 or more episodes of wheeze or diagnosed to have asthma Known or clinically recognisable congenital heart disease with cyanosis or, congestive heart failure or cardiomegaly Known or clinically recognisable acute/chronic organ system disorders including jaundice, nephrotic syndrome, severe anaemia manifested as extreme pallor etc Other infectious conditions requiring antibiotic therapy at the day of contact including meningitis, tuberculosis, dysentery, osteomyelitis, septic arthritis etc
Patient description: An 8-year-old male presents in March to the ER with fever up to 39 C, dyspnea and cough for 2 days. He has just returned from a 5 day vacation in Colorado. Parents report that prior to the onset of fever and cough, he had loose stools. He denies upper respiratory tract symptoms. On examination he is in respiratory distress and has bronchial respiratory sounds on the left. A chest x-ray shows bilateral lung infiltrates.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Encephalitis, Tick-Borne Subjects who participated in precursor Study 700401 and meet ALL of the following are eligible for participation in this study Subject / parent(s) / legal guardian(s) provide(s) written informed consent (according to national law) Subject provides written assent to the study according to age and capacity of understanding Subject received the first booster vaccination with either FSME-IMMUN 0.25 ml Junior or FSME-IMMUN 0.5 ml during the course of precursor Study 700401 Blood was drawn after the first booster vaccination in precursor Study 700401 Subject / parent(s) / legal guardian(s) understand(s) the nature of the study and is / are willing to comply with the requirements of the protocol (e.g. return for follow-up visits, completion of the Subject Diary)  Subjects who participated in precursor Study 700401 and meet ANY of the following are not eligible for participation in this study Subject received any TBE vaccination since his / her first booster vaccination in precursor Study 700401 Subject has a history of infection with or vaccination against other flaviviruses (e.g. Dengue fever, yellow fever, Japanese B encephalitis) since his / her first booster vaccination in precursor Study 700401 Subject is known to be HIV positive since his / her first booster vaccination in precursor Study 700401 (a special HIV test is not required for the purpose of the study) Subject received a blood product or immunoglobulins within 90 days before any blood draw or in the period between the blood draw and the booster vaccination (as applicable) Subject has a known or suspected problem with drug or alcohol abuse (> 4 liters of wine/week or equivalent level of other alcoholic beverages) Subject / parent(s) / legal guardian(s) is / are in a dependent relationship with the study investigator or with a study team member. Dependent relationship includes close relatives (i.e., children or grandchildren, partner / spouse, siblings) as well as employees of the investigator or the site conducting the study
Patient description: An 8-year-old male presents in March to the ER with fever up to 39 C, dyspnea and cough for 2 days. He has just returned from a 5 day vacation in Colorado. Parents report that prior to the onset of fever and cough, he had loose stools. He denies upper respiratory tract symptoms. On examination he is in respiratory distress and has bronchial respiratory sounds on the left. A chest x-ray shows bilateral lung infiltrates.

Clinical trial eligibility criteria: eligible ages (years): 1.0-12.0,  Pneumonia Children aged 1 to 12 years with acute community-acquired pneumonia (cough, tachypnea, fever and with a chest radiography with lobar, segmental or bronchopneumonia within the first 48 hours)  Severely ill patients (hospitalized in intensive care units) Pleural effusion treated with chest drainage Atelectasis detected by x-ray Pneumonia or pleural effusion in the previous six months Other pulmonary underlying disease, heart disease, cerebral palsy or immune deficiency
Patient description: An 8-year-old male presents in March to the ER with fever up to 39 C, dyspnea and cough for 2 days. He has just returned from a 5 day vacation in Colorado. Parents report that prior to the onset of fever and cough, he had loose stools. He denies upper respiratory tract symptoms. On examination he is in respiratory distress and has bronchial respiratory sounds on the left. A chest x-ray shows bilateral lung infiltrates.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Fever Analgesia Age greater than or equal to 18 years Written informed consent by the patients Medical condition necessitating the administration of antipyretic or analgesic medications  Αge lower than 18 years Lack of informed consent History of liver cirrhosis Blood creatinine greater than 3mg/dl Blood AST greater than 3 times the upper normal level according to the lab of the participating hospital History of hypersensitivity to non-steroidal ant-inflammatory drugs History of abuse of analgesics Pregnancy or lactation Fulminant hemorrhage of the upper or lower digestive tract Thrombocytopenia defined as less than 50000 platelets/μl
Patient description: An 8-year-old male presents in March to the ER with fever up to 39 C, dyspnea and cough for 2 days. He has just returned from a 5 day vacation in Colorado. Parents report that prior to the onset of fever and cough, he had loose stools. He denies upper respiratory tract symptoms. On examination he is in respiratory distress and has bronchial respiratory sounds on the left. A chest x-ray shows bilateral lung infiltrates.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Respiratory Tract Infection Adults, equal to or more than 18 years years of age Patients with respiratory tract infections, including any of the following Acute tracheitis, acute tracheobronchitis Acute sinusitis Chronic sinusitis Acute tonsillopharyngitis Acute bronchitis Mild community-acquired pneumonia Acute exacerbation of chronic bronchitis  Known hypersensitivity to or previously intolerant of macrolides Illness severe enough to warrant hospitalization or parenteral therapy Concomitant use of any of the following medications Drugs metabolized by CYP3A isozyme: alprazolam, astemizole, carbamazepine, cilostazol, cisapride, cyclosporin, disopyramide, ergot alkaloids, lovastatin, methylprednisolone, midazolam, omeprazole, oral anticoagulants (e.g. warfarin), pimozide, quinidine, rifabutin, sildenafil, simvastatin, tacrolimus, terfenadine, triazolam and vinblastine Drugs metabolized by other isozymes within CYP450 system: phenytoin, theophylline and valproate Colchicine, Digoxin, Some antiretrovirals: zidovudine and ritonavir Severe immunodeficiency and chronic disease conditions Renal or hepatic impairment (creatinine clearance under 30 mL/min, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and gamma-glutamyltransferase (GGT) equal or more than 3x higher level in comparison with the norm) Mental condition rendering the subject unable to understand the nature of the study
Patient description: An 8-year-old male presents in March to the ER with fever up to 39 C, dyspnea and cough for 2 days. He has just returned from a 5 day vacation in Colorado. Parents report that prior to the onset of fever and cough, he had loose stools. He denies upper respiratory tract symptoms. On examination he is in respiratory distress and has bronchial respiratory sounds on the left. A chest x-ray shows bilateral lung infiltrates.

Clinical trial eligibility criteria: eligible ages (years): 55.0-999.0,  Diarrhoea Clostridium Difficile Male/female patients, above 55 years of age Patient has given written informed consent/Assent to take part in the study Patients are receiving antibiotics as inpatients Patients prescribed therapy with single or multiple antibiotics (oral or IV) will be included Antibiotic therapy must be indicated for a minimum of 72 hours Patients must be able to take medication orally in the study is approved by the admitting consultant and validated by a member of the trial team within 48 hours  Age less than 55 years Pregnancy Patients on PEG feed. Diarrhoea on admission or within the preceding week Severe life-threatening illness Subjects with allergy or hypersensitivity to any component of the study product (e.g.: allergy or hypersensitivity to milk proteins) Subjects who had any surgery or intervention in the last 4 weeks Subjects enrolled in another clinical study in the last 4 weeks Subjects who are thought not to comply with the clinical study Subjects presenting with a severe evolving or active pathology or infection of the gastrointestinal tract such as inflammatory bowel disease, Crohn's disease or ulcerative colitis, diverticular disease or liver cirrhosis Any condition affecting the pancreas including acute and chronic pancreatitis Patients who had a surgical operation in their bowels in the preceding 3 months A medical condition such that the life expectancy of the patient is predicted at less than 3 months by the admitting consultant and validated by a member of the trial team Immune-suppressed patients (e.g. HIV) Steroid use of Prednisolone greater than 10mg a day (or equivalent of Dexamethasone) for over 2 weeks prior to entering the trial Patients on Cytotoxic drugs Post-transplant patients Any clinical condition affecting the pancreas including acute and chronic pancreatitis Patients with prosthetic heart valves or a history of endocarditis. Patients who have taken probiotic drinks containing live organisms or over the counter probiotic preparations in the past seven days (see Appendix 10) Foreign travel in the last 7 days
Patient description: An 8-year-old male presents in March to the ER with fever up to 39 C, dyspnea and cough for 2 days. He has just returned from a 5 day vacation in Colorado. Parents report that prior to the onset of fever and cough, he had loose stools. He denies upper respiratory tract symptoms. On examination he is in respiratory distress and has bronchial respiratory sounds on the left. A chest x-ray shows bilateral lung infiltrates.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Increased Drug Resistance Infectious Diseases Clinic practices within Denver Health's Webb Center for Primary Care Clinic practices within the University of Colorado Anschutz Campus: General Internal Medicine Clinic Clinic practices within the High Plains Network, and Clinical practices within the Wilmington Health Associates System The antibiotic prescribing patterns of primary care clinicians in these practices will be monitored over a 2 year period. Practices must be willing to assist in tracking Patient records (pediatric and adult) for conditions related to the International Classification of Diseases (ICD-9) codes associated with common infectious conditions (Upper Respiratory Infection, Acute Bronchitis, Pharyngitis, Acute Sinusitis, Otitis Media, Acute Cystitis, Cellulitis or soft tissue abscess, and Community-acquired Pneumonia) will be assessed for antibiotic prescribing 30-day events (hospitalizations Note: Emergency Department (ED) visits, or grade 3 or grade 4 abnormalities), will also be included in this study  Ob/Gyn related clinic visits will not be included in this study as these visits are not typically associated with high volumes of antibiotic prescribing for the infectious conditions of interest
Patient description: An 8-year-old male presents in March to the ER with fever up to 39 C, dyspnea and cough for 2 days. He has just returned from a 5 day vacation in Colorado. Parents report that prior to the onset of fever and cough, he had loose stools. He denies upper respiratory tract symptoms. On examination he is in respiratory distress and has bronchial respiratory sounds on the left. A chest x-ray shows bilateral lung infiltrates.

Clinical trial eligibility criteria: eligible ages (years): 0.231-999.0,  Rotavirus Gastroenteritis For cases A male or female child born after 6 March 2006 and at least 12 weeks of age Subject admitted to the study clinics/hospitals for severe gastroenteritis during the study period Onset of severe gastroenteritis ≤ 14 days prior to admission Laboratory confirmed rotavirus positive stool sample at hospital admission or during the first 48 hours of hospitalization Written informed consent obtained from the parent or guardian of the subject For controls Admitted for non-gastroenteritis causes at the same clinic/hospital as the case Living in the same neighbourhood as the case for at least three consecutive months without any symptoms of gastroenteritis or severe gastroenteritis on the day of interview of his/ her parents/ guardians Being born within +  For cases Subject has previously participated as case or control in this study Onset of severe gastroenteritis > 48 hours after admission to the hospital (nosocomial infections) For controls For hospital controls: Child who has symptoms of gastroenteritis during current hospitalization or on the day of interview of his/her parent or guardian or for neighbourhood controls: Child who has symptoms of gastroenteritis or severe gastroenteritis on the day of interview of his/her parent or guardian children with the following vaccine preventable diseases: measles, mumps, rubella, diphtheria, pertussis, tetanus, tuberculosis, invasive Haemophilus influenzae type B (Hib) infections (meningitis, bacteraemia, septic arthritis, cellulitis, and epiglottitis) and hepatitis B Child has participated in the past as a case or control in this study Child living in the same house as the case
Patient description: An 8-year-old male presents in March to the ER with fever up to 39 C, dyspnea and cough for 2 days. He has just returned from a 5 day vacation in Colorado. Parents report that prior to the onset of fever and cough, he had loose stools. He denies upper respiratory tract symptoms. On examination he is in respiratory distress and has bronchial respiratory sounds on the left. A chest x-ray shows bilateral lung infiltrates.

Clinical trial eligibility criteria: eligible ages (years): 0.0-5.0,  Rotaviral Gastroenteritis A male or female < 5 years of age at the time of admission to the study hospital for acute gastroenteritis Written informed consent obtained from the parent or guardian of the subject  The diagnosis for treatment at the study site does not acute gastroenteritis The onset of acute gastroenteritis after admission to the hospital i.e. 48 hours after hospital admission
Patient description: An 8-year-old male presents in March to the ER with fever up to 39 C, dyspnea and cough for 2 days. He has just returned from a 5 day vacation in Colorado. Parents report that prior to the onset of fever and cough, he had loose stools. He denies upper respiratory tract symptoms. On examination he is in respiratory distress and has bronchial respiratory sounds on the left. A chest x-ray shows bilateral lung infiltrates.

Clinical trial eligibility criteria: eligible ages (years): 0.0-6.0,  Nosocomial Rotavirus Gastroenteritis Viral Gastroenteritis Due to Rotavirus A male or female child aged <6 years at the time of admission in hospital. A child will become ineligible on the day of her/his sixth birthday A subject who is hospitalized with any acute gastroenteritis or rotavirus gastroenteritis during the survey period  Participants of any kind of rotavirus vaccine clinical trial